Drug Trial Radar · NCT01890434
Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)
Last checked: Nov 19, 2026Latest source record: Jul 31, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
478
Actual
Start
Aug 26, 2013
Primary completion
Aug 6, 2016
Study completion Nov 10, 2016
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Jul 1, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Subjects being evaluated for suspected or known Coronary artery Disease (CAD) based on signs and/or symptoms, will be invited to participate in the study. The duration for a subject in the study may range from 2 days to 4-6 weeks. One to four visits to the study doctor will be required. The primary objective of this study is to demonstrate that sensitivity and specificity of gadobutrol-enhanced cardiac magnetic resonance imaging (CMRI) exceed pre-specified minimum performance thresholds of 60% and 55%, respectively, and to show superior sensitivity over unenhanced wall motion CMRI at vasodilator rest/stress for the detection of significant CAD. The CMR images acquired with a uniform imaging acquisition software will be evaluated either against the results from routine clinical Coronary Angiography (CA) or Computed Tomography Angiography (CTA), which are the standard of reference. CMRI and CA/CTA images will be collected for an independent image review (blinded read).
Conditions
- Coronary Artery Disease
Interventions
Gadobutrol (Gadavist, Gadovist, BAY86-4875)Drug
Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Primary Analysis of Sensitivity Based on Blinded Readers' AssessmentTime frame: 0 to 30/40 min post-injection
- Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Sensitivity Based on Blinded Readers' AssessmentTime frame: 0 to 30/40 min post-injection
- Absence of Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Primary Analysis of Specificity Based on Blinded Readers' AssessmentTime frame: 0 to 30/40 min post-injection
- Absence of a Myocardial Perfusion Defect Excluding Significant CAD Per Participant on Gadobutrol-enhanced CMRI - Additional Secondary Analysis of Specificity Based on Blinded Readers' AssessmentTime frame: 0 to 30/40 min post-injection
- Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus Unenhanced Wall Motion CMRI Images - Primary Analysis of Sensitivity Comparison Based on the Blinded Readers' AssessmentTime frame: 0 to 30/40 min post-injection
- Presence of a Myocardial Perfusion Defect Indicating Significant CAD Per Participant on Gadobutrol-enhanced CMRI Versus Unenhanced Wall Motion CMRI Images - Additional Secondary Analysis of Sensitivity Comparison Based on the Blinded Readers' AssessmentTime frame: 0 to 30/40 min post-injection
Locations
24 sites in 4 countries. Site status is shown where the registry gives one.
Site not named
Tucson, Arizona
Site not named
Los Angeles, California
Site not named
Atlanta, Georgia
Site not named
Chicago, Illinois
Site not named
Bethesda, Maryland
Site not named
Bethesda, Maryland
Site not named
Boston, Massachusetts
Site not named
St Louis, Missouri
Site not named
Durham, North Carolina
Site not named
Cleveland, Ohio
Site not named
Columbus, Ohio
Site not named
Philadelphia, Pennsylvania
Site not named
Charleston, South Carolina
Site not named
Houston, Texas
Site not named
Charlottesville, Virginia
Site not named
Chermside, Australia
Site not named
North Adelaide, Australia
Site not named
Adelaide, South Australia, Australia
Site not named
Perth, Western Australia, Australia
Site not named
London, Ontario, Canada
Site not named
Montreal, Quebec, Canada
Site not named
Montreal, Quebec, Canada
Site not named
Singapore, Singapore
Site not named
Singapore, Singapore
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.